With our Ambifect protein therapeutic platform, Akston has developed AKS-548d to address chronic pain in dogs. In diseases such as osteoarthritis, inflammation leads to increased levels of nerve growth factor (NGF) that stimulate further inflammation and increased sensitivity to pain. When the immune system develops a robust antibody response to NGF, excess levels of NGF are removed and blocked from binding to its receptors, thereby reducing inflammation and alleviating pain.

Back to Pipeline